{
    "nct_id": "NCT06361836",
    "official_title": "A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Activity of Single Ascending Doses of SBT777101 in Subjects With Hidradenitis Suppurativa",
    "inclusion_criteria": "* Body mass index (BMI) ≤50 kg/m2, inclusive\n* Diagnosis of clinically active moderate-to-severe HS (Hurley Stage 2 or 3)\n* Total abscess or inflammatory nodule (AN) count of ≥5, affecting at least 2 distinct anatomic regions, with at least 1 accessible AN of adequate size for biopsy (diameter > 1 cm)\n* Total draining tunnel (dT) count of ≤20\n* Documented history of inadequate response or intolerance to at least a 3-month course of 1 conventional systemic therapy (e.g., antibiotic) and 1 biologic drug (e.g., adalimumab or secukinumab)\n* Doses of medications for HS must be stable for at least 5 weeks prior to study drug administration\n* Must agree to use highly effective method of contraception for at least 1 year post SBT777101 administration\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 70 Years",
    "exclusion_criteria": "* Major surgery within 12 weeks prior to screening or planned within 12 months after dosing\n* History of or current inflammatory or other autoimmune disease\n* Complex presentations of HS\n* Skin disease other than HS that may confound clinical assessments or increase subject risk in the study\n* Uncontrolled concomitant cardiovascular, nervous system, pulmonary, renal, hepatic, endocrine, or gastrointestinal disease\n* Active current infection or history of recurrent infections\n* Active or untreated latent tuberculosis\n* Primary or secondary immunodeficiency",
    "miscellaneous_criteria": ""
}